Imodium

Loperamide, the active ingredient in Imodium, is an antidiarrheal presented as an oral tablet for oral use. It reduces intestinal motility and increases water absorption, helping to control acute and chronic diarrhea as well as diarrhea‑predominant irritable bowel syndrome in adults. GNH USA supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium is an antidiarrheal medication that acts on the gastrointestinal tract to reduce stool frequency and improve consistency. Acute nonspecific diarrhea: provides rapid relief by slowing intestinal transit and enhancing fluid absorption. Chronic diarrhea: helps manage persistent loose stools associated with various gastrointestinal disorders. Irritable bowel syndrome with diarrhea (IBS‑D): reduces bowel urgency and frequency, improving quality of life.

Common Side Effects: - Abdominal cramps or discomfort - Constipation or hard stools - Nausea or mild vomiting - Dry mouth - Drowsiness or mild dizziness - Flatulence

Serious or Rare Side Effects: - Severe constipation or paralytic ileus - Toxic megacolon in predisposed patients - Allergic reactions such as rash, itching, or swelling - Cardiac arrhythmias, especially with high plasma levels - Urinary retention - Central nervous system depression when combined with other opioids

Imodium should be used with caution and under professional guidance in several situations. Pregnancy: consult a healthcare provider; safety data are limited. Breastfeeding: may be excreted in milk; use only if benefits outweigh risks. Existing constipation: avoid use as it may worsen the condition. Pediatric use: restrict to children under medical supervision and according to age‑specific dosing. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Loperamide may interact with several medicines that affect its metabolism or transport. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increased loperamide exposure. - P‑gp inhibitors (e.g., quinidine, verapamil): higher systemic levels. - Other opioid agonists: additive central nervous system depression. Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate constipation. - Other antidiarrheal products (e.g., bismuth subsalicylate): overlapping therapeutic effect.